JTO Clinical and Research Reports (Nov 2022)

BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

  • Quincy Chu, MD,
  • Natasha B. Leighl, MD,
  • Veerle Surmont, MD,
  • Carla van Herpen, MD, PhD,
  • Anne Sibille, MD,
  • Ben Markman, MD,
  • Stephen Clarke, MD,
  • Rosalyn A. Juergens, MD, PhD,
  • Mirelis Acosta Rivera, MD,
  • Vladimir Andelkovic, MD,
  • Charles M. Rudin, MD, PhD,
  • Stephanie Snow, MD,
  • Dong-Wan Kim, MD,
  • Michael Sanatani, MD,
  • Hongxia Lin, PhD,
  • Kinjal Sanghavi, PhD,
  • Sarah Tannenbaum-Dvir, MD,
  • Paul Basciano, MD,
  • Deanne Lathers, PhD,
  • Katarzyna Urbanska, PhD,
  • Georgia Kollia, PhD,
  • Chunsheng He, PhD,
  • Andrew DiPiero, BS,
  • Yu Liu, MD, PhD,
  • Neal Ready, MD, PhD

Journal volume & issue
Vol. 3, no. 11
p. 100400

Abstract

Read online

Introduction: Fucosyl-GM1 is a monosialoganglioside with limited expression in healthy tissues and high expression on SCLC cells. BMS-986012 is a nonfucosylated, first-in-class, fully human immunoglobulin G1 monoclonal antibody that binds to fucosyl-GM1. Methods: CA001-030 is a phase 1/2, first-in-human study of BMS-986012 as monotherapy or in combination with nivolumab for adults with relapsed or refractory SCLC. Safety is the primary end point. Additional end points include objective response rate, duration of response, progression-free survival, pharmacokinetics, and overall survival. Results: Patients (BMS-986012 monotherapy, n = 77; BMS-986012 + nivolumab, n = 29) were predominantly of male sex (58%), 63 years old (mean), current or past tobacco users (97%), and treated previously with first-line systemic therapy (99%). The most common treatment-related adverse event was pruritus (n = 95 [90%]). Grade 4 treatment-related adverse events were reported in 2% (n = 2) of patients. The objective response rate (95% confidence interval [CI]) was higher with BMS-986012 plus nivolumab (38% [20.7%–57.7%]) than with monotherapy (4% [0.8%–11.0%]). Median (95% CI) duration of response with BMS-986012 plus nivolumab was 26.4 (4.4–not reached) months. Progression-free survival (95% CI) at 24 weeks with monotherapy and BMS-986012 plus nivolumab was 12.2% (6.0%–20.7%) and 39.3% (21.7%–56.5%), respectively. The pharmacokinetics profile of monotherapy and BMS-986012 plus nivolumab suggested dose proportionality across the tested dose range. Median overall survival (95% CI) with monotherapy and BMS-986012 plus nivolumab was 5.4 (4.0–7.3) and 18.7 (8.2–37.3) months, respectively. Conclusions: BMS-986012 in combination with nivolumab represents a well-tolerated, potential new therapy for relapsed or refractory SCLC. BMS-986012 is currently being explored in combination with carboplatin, etoposide, and nivolumab as a first-line therapy in extensive-stage SCLC (NCT04702880).

Keywords